These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1812352)

  • 1. A new macrocyclic MRI contrast agent: Gd MCTA complex.
    Schaefer M; Meyer D; Beaute S; Doucet D
    Magn Reson Med; 1991 Dec; 22(2):238-41. PubMed ID: 1812352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gd-DOTA, a potential MRI contrast agent. Current status of physicochemical knowledge.
    Meyer D; Schaefer M; Bonnemain B
    Invest Radiol; 1988 Sep; 23 Suppl 1():S232-5. PubMed ID: 3198351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new biodegradable and biocompatible gadolinium (III) -polymer for liver magnetic resonance imaging contrast agent.
    Xiao Y; Xue R; You T; Li X; Pei F
    Magn Reson Imaging; 2015 Jul; 33(6):822-8. PubMed ID: 25839395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel gadolinium(III) polyaminocarboxylate macrocyclic complexes as potential magnetic resonance imaging contrast agents.
    Chan KW; Barra S; Botta M; Wong WT
    J Inorg Biochem; 2004 May; 98(5):677-82. PubMed ID: 15134912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadolinium cryptelates as MR contrast agents.
    Knop RH; Frank JA; Dwyer AJ; Girton ME; Naegele M; Schrader M; Cobb J; Gansow O; Maegerstadt M; Brechbiel M
    J Comput Assist Tomogr; 1987; 11(1):35-42. PubMed ID: 3805426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and performance of biocompatible gadolinium polymer as liver-targeting magnetic resonance imaging contrast agent.
    Hu T; Wan C; Zhan Y; Li X; Zheng Y
    J Biosci Bioeng; 2024 Feb; 137(2):134-140. PubMed ID: 38195341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging.
    Chong HS; Garmestani K; Bryant LH; Milenic DE; Overstreet T; Birch N; Le T; Brady ED; Brechbiel MW
    J Med Chem; 2006 Mar; 49(6):2055-62. PubMed ID: 16539394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadolinium-DOTA enhanced MR imaging of intracranial lesions.
    Parizel PM; Degryse HR; Gheuens J; Martin JJ; Van Vyve M; De La Porte C; Selosse P; Van de Heyning P; De Schepper AM
    J Comput Assist Tomogr; 1989; 13(3):378-85. PubMed ID: 2723166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadolinium(III) complexes of mono- and diethyl esters of monophosphonic acid analogue of DOTA as potential MRI contrast agents: solution structures and relaxometric studies.
    Lebdusková P; Hermann P; Helm L; Tóth E; Kotek J; Binnemans K; Rudovský J; Lukes I; Merbach AE
    Dalton Trans; 2007 Jan; (4):493-501. PubMed ID: 17213936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of polyaza macrocyclic methylene phosphonate chelates of Gd3+ ions as MRI contrast agents.
    Geraldes CF; Brown RD; Cacheris WP; Koenig SH; Sherry AD; Spiller M
    Magn Reson Med; 1989 Jan; 9(1):94-104. PubMed ID: 2540397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of nuclear magnetic relaxation dispersion (NMRD) profiles in MRI contrast media development.
    Muller RN; Vander Elst L; Rinck PA; Vallet P; Maton F; Fischer H; Roch A; Van Haverbeke Y
    Invest Radiol; 1988 Sep; 23 Suppl 1():S229-31. PubMed ID: 3198350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate of arabinogalactan as a potential liver-targeting magnetic resonance imaging contrast agent.
    Xiao Y; Xue R; You T; Li X; Pei F; Wang X; Lei H
    Carbohydr Res; 2014 Aug; 395():9-14. PubMed ID: 24995911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclen-based Gd
    Rashid HU; Martines MAU; Jorge J; de Moraes PM; Umar MN; Khan K; Rehman HU
    Bioorg Med Chem; 2016 Nov; 24(22):5663-5684. PubMed ID: 27729196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.
    Ye Z; Zhou Z; Ayat N; Wu X; Jin E; Shi X; Lu ZR
    Contrast Media Mol Imaging; 2016; 11(1):32-40. PubMed ID: 26218648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo magnetic resonance imaging of mice liver tumors using a new gadolinium-based contrast agent.
    Chen SH; Kuo YT; Cheng TL; Chen CY; Chiu YY; Lai JJ; Chang CC; Jaw TS; Wang YM; Liu GC
    Kaohsiung J Med Sci; 2013 May; 29(5):246-53. PubMed ID: 23639510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.
    Murata N; Gonzalez-Cuyar LF; Murata K; Fligner C; Dills R; Hippe D; Maravilla KR
    Invest Radiol; 2016 Jul; 51(7):447-53. PubMed ID: 26863577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMRD assessment of Gd-DTPA-bis(methoxyethylamide), (Gd-DTPA-BMEA), a nonionic MRI agent.
    Adzamli K; Periasamy MP; Spiller M; Koenig SH
    Invest Radiol; 1999 Jun; 34(6):410-4. PubMed ID: 10353033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relaxometry, animal biodistribution, and magnetic resonance imaging studies of some new gadolinium (III) macrocyclic phosphinate and phosphonate monoester complexes.
    Geraldes CF; Sherry AD; Lázár I; Miseta A; Bogner P; Berenyi E; Sumegi B; Kiefer GE; McMillan K; Maton F
    Magn Reson Med; 1993 Dec; 30(6):696-703. PubMed ID: 8139451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surface modification of PLGA nanospheres with Gd-DTPA and Gd-DOTA for high-relaxivity MRI contrast agents.
    Ratzinger G; Agrawal P; Körner W; Lonkai J; Sanders HM; Terreno E; Wirth M; Strijkers GJ; Nicolay K; Gabor F
    Biomaterials; 2010 Nov; 31(33):8716-23. PubMed ID: 20797782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.